Tesamorelin - Valar Peptides
For research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure or prevent any disease.

Free US shipping for orders above $200 • Save 20% on 10-vial bundles

Tesamorelin

Tesamorelin

Starting at $37

Independently tested by Novagen Analytical Labs

Batch TESA57445 · HPLC tested 22 April 2026

Verify this batch with the lab View the certificate

Every batch we sell carries its own verification key. This one is NGL-2026-6ZKG17. Enter it on the laboratory's own website and it returns the certificate for this exact batch. That page belongs to the lab, not to us.

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue peptide designed to stimulate the natural release of growth hormone (GH) from the pituitary gland. By mimicking the action of endogenous GHRH, Tesamorelin promotes GH secretion in a physiological pattern, supporting research into metabolism, muscle growth, and fat regulation.

This peptide is a stable, high-purity formulation ideal for scientific and laboratory research. Unlike direct HGH injections, Tesamorelin works indirectly encouraging the body’s own GH production rhythm rather than suppressing it.

Choose your strength
Choose your quantity

This order qualifies for free US shipping.

In Stock

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

Ships from the USADispatched from our United States warehouse
3 to 5 business daysStandard delivery, US wide
International shippingFree on orders over $350
TrackedTracking sent when it leaves the warehouse
Bacteriostatic Water 10ml
Bacteriostatic water3 ml per peptide vial. One 10 ml vial covers three, $11 each. Required to reconstitute.
Add
Often researched together
RetatrutideRetatrutideStarting at $72Add to cart
IpamorelinIpamorelinStarting at $33Add to cart
SemaglutideSemaglutideStarting at $51Add to cart
Title Range Discount
Volume pricing - 10% at 5+, 20% at 10+ 5 - 9 10%
Volume pricing - 10% at 5+, 20% at 10+ 10 + 20%

Data Sheet

Molecular Formula C₂₂₁H₃₆₆N₇₂O₆₇S
CAS Number 218949-48-5
Molar Mass 5135.86 g/mol
Amino Acid Sequence Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH)
PubChem CID 146681838
Primary Research Area Reduce Visceral Adipose Tissue (VAT) in HIV-infected patients with lipodystrophy
Insulin Resistance
Obesity
Nonalcoholic Fatty Liver Disease (NAFLD)
GHRH Receptor Agonist
Stimulate GH/IGF-1
Improve Metabolic Profile
Improve Fat Quality
Purity ≥98%
Research Summary Description
Tesamorelin improves fat quality independent of changes in fat quantity Summary: A notable finding is Tesamorelin's ability to improve ""fat quality"" independently of changes in fat quantity. Stanley et al. (2021) demonstrated that Tesamorelin increased both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) density in people living with HIV (PLWH).

Citation: Stanley, T. L., Stanley, A. N., Stanley, T. L., & Grinspoon, S. K. (2021). Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. Journal of Acquired Immune Deficiency Syndromes, 87(2), e213.
The growth hormone releasing hormone analogue, Tesamorelin, decreases muscle fat and increases muscle area in adults with HIV Summary: This exploratory secondary analysis of two clinical trials investigated the effects of tesamorelin on skeletal muscle fat and area in people living with HIV (PLWH) with abdominal obesity. The study found that tesamorelin significantly increased the density (less fat) and area of several truncal muscle groups in responders (those who experienced a significant decrease in visceral adipose tissue).

Citation: Adrian, S., Scherzinger, A., Sanyal, A., & Grinspoon, S. K. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. BMC Medicine, 17(1), 173.
Effects of Tesamorelin on nonalcoholic fatty liver disease in HIV: A randomized, double-blind, multicenter trial Summary: This randomized, double-blind, placebo-controlled trial investigated the effects of tesamorelin on nonalcoholic fatty liver disease (NAFLD) in people living with HIV (PLWH). The study found that tesamorelin significantly reduced hepatic fat fraction (HFF) compared to placebo after 12 months, suggesting a beneficial effect on liver fat. Glucose parameters did not significantly differ between groups.

Citation: Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Aepfelbacher, J., Kellogg, A., ... & Grinspoon, S. K. (2020). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial. Gastroenterology, 158(1), 132–142.e5.

Tesamorelin improves fat quality independent of changes in fat quantity

Summary: A notable finding is Tesamorelin's ability to improve ""fat quality"" independently of changes in fat quantity. Stanley et al. (2021) demonstrated that Tesamorelin increased both visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) density in people living with HIV (PLWH).

Citation: Stanley, T. L., Stanley, A. N., Stanley, T. L., & Grinspoon, S. K. (2021). Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. Journal of Acquired Immune Deficiency Syndromes, 87(2), e213.

The growth hormone releasing hormone analogue, Tesamorelin, decreases muscle fat and increases muscle area in adults with HIV

Summary: This exploratory secondary analysis of two clinical trials investigated the effects of tesamorelin on skeletal muscle fat and area in people living with HIV (PLWH) with abdominal obesity. The study found that tesamorelin significantly increased the density (less fat) and area of several truncal muscle groups in responders (those who experienced a significant decrease in visceral adipose tissue).

Citation: Adrian, S., Scherzinger, A., Sanyal, A., & Grinspoon, S. K. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. BMC Medicine, 17(1), 173.

Effects of Tesamorelin on nonalcoholic fatty liver disease in HIV: A randomized, double-blind, multicenter trial

Summary: This randomized, double-blind, placebo-controlled trial investigated the effects of tesamorelin on nonalcoholic fatty liver disease (NAFLD) in people living with HIV (PLWH). The study found that tesamorelin significantly reduced hepatic fat fraction (HFF) compared to placebo after 12 months, suggesting a beneficial effect on liver fat. Glucose parameters did not significantly differ between groups.

Citation: Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Aepfelbacher, J., Kellogg, A., ... & Grinspoon, S. K. (2020). Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial. Gastroenterology, 158(1), 132–142.e5.

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping